Polaris Group (TPE:6550)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
46.30
-2.05 (-4.24%)
Feb 21, 2025, 1:30 PM CST
-36.05%
Market Cap 34.55B
Revenue (ttm) 75.65M
Net Income (ttm) -2.25B
Shares Out 746.20M
EPS (ttm) -3.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,882,536
Average Volume 624,443
Open 47.50
Previous Close 48.35
Day's Range 45.80 - 47.50
52-Week Range 43.00 - 78.00
Beta 0.58
RSI 44.81
Earnings Date May 9, 2025

About Polaris Group

Polaris Group, together with its subsidiaries, offers biotechnology, drug testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It develops ADI-PEG 20 for the treatment of various cancer indications. It also provides healthcare consulting, staffing, and MDS solutions. The company was founded in 1988 and is based in Tampa, Florida. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1988
Employees 165
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6550
Full Company Profile

Financial Performance

In 2023, Polaris Group's revenue was 7.48 million, an increase of 16.18% compared to the previous year's 6.44 million. Losses were -1.58 billion, 37.1% more than in 2022.

Financial Statements

News

There is no news available yet.